Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Enhanced antileukemic activity of momelotinib in combination with venetoclax and azacitidine compared to gilteritinib-based combination

View Full Paper
Ask AI
Bookmark
Share

Authors

SOShane W. O’BrienMMMichael T. McCabe

Discussion

Loading...

Member takes

Overview

Preclinical data demonstrate enhanced therapeutic effects in AML with momelotinib, venetoclax, and azacitidine combinations, suggesting a promising approach.

Key Points

  • To evaluate the efficacy of momelotinib combined with venetoclax and azacitidine against acute myeloid leukemia (AML).
  • Preclinical analysis using AML patient-derived xenograft (PDX) mouse models.
  • Assessment of survival and leukemic clearance with different drug combinations.
  • Evaluation of the cytotoxic response in FLT3 wild-type and mutant AML cells.
  • Momelotinib combined with venetoclax and azacitidine exhibited synergistic cytotoxic responses.
  • This combination led to prolonged survival in AML PDX models compared to gilteritinib-based combinations.
  • Responses in the momelotinib combination were effective across both FLT3 mutant and wild-type AML.

Cite This Study

O’Brien et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc2bhttps://doi.org/10.1182/blood-2025-7850
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Negative feedback regulation of nfkb, MAPK, and JAK-STAT drives adaptive resistance to gilteritinib in AML2025
  2. 2Momelotinib-mediated transcriptional reprogramming induces synthetic lethal interaction with calcineurin-NFAT signaling2025
  3. 3Discovery of drug combinations with momelotinib to improve myelofibrosis outcomes2025
  4. 4Abstract 5870: Momelotinib: Unique polypharmacology and novel combination strategies for myelofibrosis and beyond2026
  5. 5Combined FLT3 and EZH1/2 inhibition reduces LSCs and promotes myeloid differentiation in PDX models of AML2025